French work on resuming full ultrasound service
This article was originally published in Clinica
Executive Summary
The last couple of weeks have seen a flurry of legislative activity on the French draft ruling on diagnosing handicap in the unborn child, known as the Perruche case. This issue is being dealt with urgently, since until the government establishes a legal basis that does not leave ultrasound technicians vulnerable to being sued for failing to diagnose abnormalities, normal ultrasound services are threatened (see Clinica No 990, p 3 and No 992, p3 and No 993, p 4).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.